ITT:NYSEITT Inc. Analysis
Data as of 2026-04-11 - not real-time
$216.90
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
ITT Inc. is trading at $216.9, just shy of its 52‑week high of $218.99, with the 20‑day SMA ($192.88) well below price and a bullish MACD histogram (+3.43) indicating upward momentum. However, the RSI of 71 places the stock in overbought territory and the 30‑day volatility of nearly 40% combined with a beta of 1.22 signal heightened short‑term price swings. Fundamentals remain robust: revenue grew 13.5% YoY to $3.94 bn, EPS jumped to $6.12 with forward EPS projected at $8.87, and free cash flow exceeds $444 m, supporting a low payout ratio (~23%). The recent $4.78 bn cash‑and‑stock acquisition of SPX FLOW adds a strategic industrial process platform, expanding global exposure and reinforcing long‑term growth prospects.
Valuation metrics show a forward PE of 24.4 versus an industry average of 30.9, yet the DCF fair value ($127.85) is well below the current price, flagging potential overvaluation. The dividend yield of 0.71% appears sustainable given strong cash balances and modest leverage (debt‑to‑equity 21%). Overall, the stock presents a blend of growth momentum and valuation caution, with the acquisition likely to drive earnings expansion over the medium horizon.
Valuation metrics show a forward PE of 24.4 versus an industry average of 30.9, yet the DCF fair value ($127.85) is well below the current price, flagging potential overvaluation. The dividend yield of 0.71% appears sustainable given strong cash balances and modest leverage (debt‑to‑equity 21%). Overall, the stock presents a blend of growth momentum and valuation caution, with the acquisition likely to drive earnings expansion over the medium horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI in overbought zone suggests limited upside
- Bullish MACD but price near resistance
- High short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue growth of 13.5% and EPS acceleration
- Strategic SPX FLOW acquisition expanding addressable market
- Target median price of $234 indicating ~8% upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustainable dividend with low payout ratio
- Strong free cash flow and modest leverage
- Diversified global footprint reducing concentration risk
Key Metrics & Analysis
Financial Health
Revenue Growth13.50%
Profit Margin12.39%
P/E Ratio35.4
ROE14.29%
ROA8.13%
Debt/Equity21.20
P/B Ratio4.6
Op. Cash Flow$668.3M
Free Cash Flow$445.0M
Industry P/E30.9
Technical Analysis
TrendNeutral
RSI71.3
Support$180.10
Resistance$218.99
MA 20$192.88
MA 50$195.20
MA 200$179.30
MACDBullish
VolumeIncreasing
Fear & Greed Index87.09
Valuation
Fair Value$127.85
Target Price$233.92
Upside/Downside7.85%
GradeOvervalued
TypeGrowth
Dividend Yield0.71%
Risk Assessment
Beta1.22
Volatility39.79%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.